Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and Silicon Valley Bank BURLINGTON, Mass. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc.[…]

Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission   Company successfully completed the first of two planned human factors studies Company accelerates timeline and now expects resubmission of[…]

BURLINGTON, Mass. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the resubmission would be under the current NDA Company accelerates timeline and now expects resubmission of[…]

BURLINGTON, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Type C Meeting to solidify re-filing plans for FUROSCIX® scheduled with the U.S. Food and Drug Administration ( FDA ) for June 2019 Resubmission of FURSOCIX New Drug Application (NDA) with the FDA in 2020 Balance sheet remains strong with over $83 million in cash BURLINGTON, Mass.[…]

Signed development agreement with West Pharmaceutical Services for next-generation FUROSCIX ® On-Body Infusor Resubmission of FURSOCIX with the U.S. Food and Drug Administration ( FDA ) by year-end 2020 Balance sheet remains strong with over $89 million in cash BURLINGTON, Mass.[…]

BURLINGTON, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today[…]

Advancing FUROSCIX ® with the SmartDose ® Drug Delivery System Forecast 2018 year-end cash of $82 - $87 million and 2019 expenditures of  $8 - $10 million per quarter BURLINGTON, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on[…]